Persistence and switching patterns of migraine prophylactic medications in Canada: A retrospective claims analysis comparing adherence and evaluating the economic burden of illness.
PAPERS | January 7-13, 2023 | |
Source: J Pharm Pharm Sci 2023; 25. doi: 10.18433/jpps33158Authors: Jo AO, Zhang S, Bleibdrey N, Zimskind D, Keshvani N, Chalmers R
To describe patient characteristics, treatment patterns, and the burden of illness among adult migraine patients in Canada prescribed migraine prophylactics. Little is known about the relative persistence of treatments in the real-world setting and the impact of migraine prophylactic therapy on patients. As a result, migraine care in Canada continues to inadequately serve patients suffering from frequent headache days, reflecting a large unmet need.
Pubmed ID: http://www.ncbi.nlm.nih.gov/pubmed/36623477?dopt=Abstract